Steroid Hormones Library

Steroid Hormones DMPK and Bioanalytical Services

Steroid hormone bioanalysis introduces two enzyme classes not seen anywhere else in this library: 11β-hydroxysteroid dehydrogenase (11β-HSD) and deiodinases. Hydrocortisone and prednisone are 11β-HSD prodrugs — not CYP, not UGT, not esterase — requiring NAD+/NADP+ cofactor systems distinct from every other prodrug activation assay in this collection. Liothyronine (T3) is metabolized by deiodinases via halogen removal — a reaction mechanism unrelated to oxidation, reduction, hydrolysis, or glucuronidation. Beyond these two novel enzyme classes, the remaining five compounds span CYP3A4 metabolism (testosterone, progesterone), CYP3A4 induction + P-gp (dexamethasone), Phase I+II dual metabolism (estradiol), and non-metabolized excretion (prednisolone) — six distinct analytical approaches for eight compounds.

Creative Proteomics provides 11β-HSD prodrug activation monitoring, deiodinase metabolism profiling, CYP3A4 inducer+substrate DDI risk assessment, Phase I+II dual-cofactor profiling, and non-metabolized steroid hormone disposition.

11β-HSD Prodrug ActivationHydrocortisone and prednisone are activated by 11β-HSD — a first in this library. Requires NAD+/NADP+, not CYP or UGT cofactors.
Deiodinase: Halogen RemovalT3 metabolism via deiodinases is a novel enzyme class — not oxidation or glucuronidation.
Dexamethasone: CYP3A4 Inducer + P-gpCYP3A4 substrate AND inducer with P-gp transport — three analytical dimensions.
Steroid Enzyme Diversity DMPK Strategy Map
11β-HSD Prodrug Activation (2 compounds)Hydrocortisone and prednisone require 11β-HSD with NAD+/NADP+ cofactor — the first appearance of this enzyme class in the library.
🧬
CYP3A4 Inducer + Substrate + P-gp (Dexamethasone)CYP3A4 metabolism, CYP3A4 induction (accelerated co-substrate clearance), and P-gp transport — three DDI dimensions in one steroid.
📊
Deiodinase (T3) + Phase I+II (Estradiol)T3: halogen removal by deiodinases. Estradiol: CYP3A4/CYP1A2 Phase I + UGT Phase II — dual-cofactor required.
🔬
CYP Phase I + Non-Metabolized (4 compounds)Testosterone/progesterone: CYP3A4 Phase I. Prednisolone: excreted unchanged. Shared CYP framework serves multiple steroids.
Steroid hormone enzyme audit before method development.Creative Proteomics maps each compound's enzyme system — 11β-HSD, deiodinase, CYP3A4, or none — because hydrocortisone needs NAD+, T3 needs deiodinase cofactors, and estradiol needs NADPH+UDPGA. Six analytical approaches, one class.
Steroid Hormone Drug Index

Find the Steroid Hormone Behind the Study

Steroid hormone studies split across novel and standard enzyme systems: 11β-HSD prodrug activation, deiodinase metabolism, CYP3A4 metabolism, CYP induction, Phase I+II dual metabolism, and non-metabolized excretion. Use the index to identify the enzyme system before method development.

A–Z anchors
Filter by study tagsSelect a field to reveal its tags.
8 entries · Page 1 of 4
Analytical Pain Points

What Drives Assay Failure in Steroid Hormone Studies?

Steroid hormone assays fail when novel enzyme systems are treated as standard CYP substrates. 11β-HSD uses NAD+/NADP+, not NADPH. Deiodinases perform halogen removal, not oxidation. Applying a CYP protocol to hydrocortisone or T3 uses the wrong cofactor for the wrong reaction mechanism.

11β-HSD Is Not CYP or UGT or Esterase

Hydrocortisone and prednisone are 11β-HSD prodrugs requiring NAD+/NADP+ cofactor — not NADPH (CYP), not UDPGA (UGT). A standard CYP protocol produces zero activation data.

Our response11β-HSD-specific incubation with NAD+/NADP+ cofactor and prodrug-to-active conversion monitoring.
Phase I & II Metabolite Characterization →

T3: Deiodinase Metabolism Is Halogen Removal

Liothyronine (T3) is metabolized by deiodinases — removing iodine atoms from the thyronine ring. Standard CYP oxidation or UGT glucuronidation assays measure the wrong reaction type.

Our responseDeiodinase-specific incubation with tissue microsome preparations and iodine-release-based metabolite detection.
Metabolite Identification →

Dexamethasone: Inducer + Substrate + P-gp

Dexamethasone is a CYP3A4 substrate, CYP3A4 inducer, and P-gp substrate. CYP metabolism alone captures one dimension; induction accelerates co-substrate clearance; P-gp adds efflux.

Our responseHepatocyte CYP3A4 induction assay with co-substrate clearance monitoring and P-gp substrate classification.
DDI Screening Services →

Estradiol: Phase I+II Dual Metabolism

Estradiol undergoes CYP3A4/CYP1A2 Phase I and UGT Phase II glucuronidation. NADPH+UDPGA dual-cofactor required. Single-cofactor protocols capture half the clearance.

Our responseDual-cofactor (NADPH+UDPGA) incubation for CYP Phase I and UGT Phase II metabolite profiling.
Phase I & II Metabolite Characterization →

Six Approaches, Eight Compounds, One Class

11β-HSD prodrug, deiodinase, CYP3A4 inducer+P-gp, CYP Phase I, Phase I+II, and non-metabolized — each requires distinct cofactor and enzyme conditions.

Our responseEnzyme-matched panels with 11β-HSD, deiodinase, CYP induction, CYP/UGT dual-cofactor, and non-metabolized arms.
Custom Panels →
Focused Service Paths

Four Practical Routes for Steroid Hormone Studies

Steroid workflows should be selected by enzyme system: 11β-HSD prodrug activation for hydrocortisone and prednisone; CYP3A4 inducer DDI for dexamethasone; deiodinase metabolism for T3; CYP/UGT Phase I+II for estradiol; CYP Phase I for testosterone and progesterone; non-metabolized disposition for prednisolone; or enzyme-matched panels for mixed studies.

1

11β-HSD Prodrug Activation

For hydrocortisone and prednisone — 11β-HSD-mediated prodrug-to-active conversion with NAD+/NADP+ cofactor.

  • 11β-HSD-specific incubation system
  • NAD+/NADP+ cofactor supplementation
  • Prodrug-to-active metabolite quantification
Phase I & II Metabolite Characterization →
2

CYP3A4 Inducer + Substrate DDI

For dexamethasone — CYP3A4 metabolism, CYP3A4 induction, and P-gp transporter profiling. Three DDI dimensions.

  • Hepatocyte CYP3A4 induction assay
  • Co-substrate clearance acceleration monitoring
  • P-gp substrate classification
DDI Screening Services →
3

Deiodinase & Phase I+II Dual Profiling

For T3 (deiodinase) and estradiol (CYP+UGT dual-cofactor) — two non-standard enzyme systems requiring mechanism-specific protocols.

  • Deiodinase tissue microsome incubation (T3)
  • NADPH+UDPGA dual-cofactor (estradiol)
  • CYP Phase I + UGT Phase II (estradiol)
Metabolite Identification →
4

Custom Enzyme-Matched Steroid Panel

For multi-steroid studies spanning 11β-HSD, CYP inducer, deiodinase, CYP/UGT, and non-metabolized mechanisms.

  • 11β-HSD arm (hydrocortisone, prednisone)
  • CYP induction arm (dexamethasone)
  • Deiodinase + CYP/UGT + non-metabolized arms
Custom Multi-Analyte Drug Panels →
Project Inquiry

Need Support for a Novel or Unlisted Steroid Hormone?

If your steroid hormone involves 11β-HSD, deiodinase, CYP induction, Phase I+II dual metabolism, or non-standard enzyme systems — Creative Proteomics defines the enzyme system before method development.

Creative Proteomics classifies each steroid by enzyme system: 11β-HSD, deiodinase, CYP, UGT, or none — then selects cofactor, incubation conditions, and analytical readout accordingly.

Target steroid hormone
11β-HSD / CYP / deiodinase / none
Cofactor requirement
CYP induction / P-gp status
Phase II UGT if applicable
Panel requirements

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

inquiry
Online Inquiry